MUMBAI, India, July 13 -- Intellectual Property India has published a patent application (202641081445 A) filed by Dr. R. Nithyatharani; Dr. Jyothi Kaparapu; S. Haritharaj; Dr. Athiappan Murugan; Mr. Ram Pachauri; Dr. Sudhakar Cheedi; Ms. R. Priyadharshini; and Dr. M. Vinoth on July 01, 2026, for A Standardized Moringa Seed-Derived Bioactive Composition For Anticancer Activity And Process For Preparation Thereof.
Inventors include Dr. R. Nithyatharani; Dr. Jyothi Kaparapu; S. Haritharaj; Dr. Athiappan Murugan; Mr. Ram Pachauri; Dr. Sudhakar Cheedi; Ms. R. Priyadharshini; and Dr. M. Vinoth.
The application for the patent was published on July 10, 2026, under issue no. 28/2026.
Abstract: [041] The present invention discloses a standardized moringa seed-derived bioactive composition for anticancer activity and a process for preparation thereof. The composition comprises a marker-enriched moringa seed fraction obtained from defatted moringa seed material, a stabilizing carrier matrix, and one or more acceptable excipients. The process includes cleaning, drying, milling, defatting, controlled extraction, optional enzymatic activation, filtration, concentration, drying, marker-based standardization, and carrier- assisted formulation of moringa seed material. The standardized fraction is enriched with anticancer-associated phytochemical constituents selected from glucosinolate-derived compounds, isothiocyanate-related compounds, phenolic compounds, flavonoid compounds, sterol compounds, and combinations thereof. The carrier matrix improves stability, dispersibility, and controlled release of the active fraction in a biological medium. The composition is configured to inhibit abnormal cell proliferation, induce apoptosis- associated changes, modulate oxidative stress, alter cell-cycle progression, and reduce non-specific cytotoxicity compared with crude moringa seed extract. Accompanied Drawing [FIGS. 1-2]
Disclaimer: Curated by HT Syndication.
